Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Gastrointestinal Neoplasms
  • Piperazines
  • Proto-Oncogene Proteins c-kit
  • Pyrimidines
  • Receptor, Platelet-Derived Growth Factor alpha

abstract

  • Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib. PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.

publication date

  • December 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2003.04.190

PubMed ID

  • 14645423

Additional Document Info

start page

  • 4342

end page

  • 9

volume

  • 21

number

  • 23